deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT05714553

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion Study to Assess the Safety, Pharmacokinetics and Efficacy of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Approved Agents in Patients With Advanced Solid Tumours

Sponsor: NuCana plc

Conditions Advanced Cancer Advanced Solid Tumor Classical Hodgkin Lymphoma Endometrial Carcinoma Gastric Cancer Head and Neck Squamous Cell Carcinoma MSI-H Colorectal Cancer Melanoma Metastatic Cancer Neoplasm Malignant Non Small Cell Lung Cancer Oesophageal Carcinoma Pleural Mesothelioma Renal Cell Carcinoma Subungual Squamous Cell Carcinoma Triple Negative Breast Cancer Urothelial Carcinoma
Interventions Docetaxel Fosifloxuridine Nafalbenamide Leucovorin Pembrolizumab
Updated 7 times since 2023 Last updated: Jul 15, 2025 Started: Mar 8, 2023 Primary completion: May 30, 2025 Completion: May 30, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The NuTide:303 study was terminated at NuCana's discretion due to refinement of the pipeline strategy. The overall risk benefit assessment of NUC-3373 remains positive and future NUC-3373 studies are under consideration.

Other terminated trials from NuCana plc

More terminations from NuCana plc

Other Advanced Cancer trials with similar outcome

Browse all Advanced Cancer trials

This PHASE1/PHASE2 trial investigates Advanced Cancer and Advanced Solid Tumor and is currently terminated or withdrawn. NuCana plc leads this study, which shows 7 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Mar 2023 – ~Jul 2023 · 4 months · monthly snapshotNot Yet Recruiting~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotRecruiting~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshotRecruiting~Oct 2024 – ~Apr 2025 · 6 months · monthly snapshotRecruiting~Apr 2025 – ~Aug 2025 · 4 months · monthly snapshotRecruiting~Aug 2025 – present · 11 months · monthly snapshotTerminated

Change History

7 versions recorded

  1. Aug 2025 — Present [monthly]

    Terminated PHASE1/PHASE2

    Status: Recruiting → Terminated

  2. Apr 2025 — Aug 2025 [monthly]

    Recruiting PHASE1/PHASE2

  3. Oct 2024 — Apr 2025 [monthly]

    Recruiting PHASE1/PHASE2

  4. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE1/PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 2 earlier versions

  1. Jul 2023 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  2. Mar 2023 — Jul 2023 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • NuCana plc
Data source: NuCana plc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations